Sulanemadlin is under clinical development by Aileron Therapeutics and currently in Phase I for Chemotherapy Induced Myelosuppression. According to GlobalData, Phase I drugs for Chemotherapy Induced Myelosuppression have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sulanemadlin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sulanemadlin overview

Sulanemadlin (ALRN-6924) is under development for the treatment of solid tumors, small cell lung cancer and pediatric tumors including lymphomas, acute myeloid leukemia acute lymphocytic leukemia, chemotherapy induced myelosuppression in patients with TP53-mutated HER2- breast cancer, retinoblastoma, hepatoblastoma, acute radiation induced toxicity, brain tumor, liposarcoma, ER positive/HER2 negative breast cancer, metastatic breast cancer and chemotherapy-induced hair loss. It is administered through the intravenous route. The drug candidate is a synthetic peptide which is developed based on stapled peptide technology that locks the peptides into certain folded shapes (biologically active shape), that are resistant to proteases. It acts by targeting murine double minute 2 (MDM2) and murine double minute X (MDMX).

The drug candidate was also under development for the treatment of adult peripheral T-cell lymphoma, lymphoma's, acute myeloid leukemia,p53-mutant chemotherapy induced myelosuppression in small cell lung cancer patients, myelodysplastic syndrome and non-small cell lung cancer.

Aileron Therapeutics overview

Aileron Therapeutics is a biopharmaceutical company. The company discovers, develops, and commercializes novel class of therapeutics. It provides products such as ALRN-692 which is a peptide drug used to treat patients with p53-mutated cancer. ALRN-6924 as an anti-cancer agent including a single-agent Phase 1 trial in solid tumor and lymphoma patients; a Phase 2a trial for the treatment of peripheral T-cell lymphoma; a single-agent Phase 1 trial for the treatment of acute myeloid leukemia, or AML, and advanced high-risk myelodysplastic syndrome (MIDS). The company partners with research organizations to provide its products. Aileron Therapeutics is headquartered in Boston, Massachusetts, the US.

For a complete picture of Sulanemadlin’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.